Providing the only nonsurgical treatment for tympanic membrane perforations


Tympanogen, Inc. is a medical device company whose mission is to set a new standard of care for treating chronic tympanic membrane perforations. These perforations often result from pressure-equalizing tubes needed to relieve middle ear infections. If left untreated, these perforations may lead to recurrent infection, hearing loss, nerve, and brain damage. Current therapies require invasive surgeries with potentially low success rates.

Our patent-pending gel patch product, called Perf-FixTM, replaces the current surgical therapy with an in-clinic procedure. Preliminary studies have shown Perf-Fix TM to double the success rate of the current surgical procedure while actively preventing recurrent infection. Perf-FixTM is the singular nonsurgical alternative among currently available products.

Perf-FixTM is still in development, and is not for sale in the United States or any country.


May 29, 2015 | Tympanogen Awarded Research Commercialization Grant

read more

March 27, 2015 | Norfolk Startup Wins InnovateHer Challenge

read more

May 15, 2014 | NASA Human Health & Performance Center. 2014 Rice Business Plan Competition Winner

read more

May 6, 2014 | Tympanogen Wins 2nd Overall at International Business Model Competition

read more

April 22, 2014 | Biotech Startup Tympanogen Wins 5th Place in World's Largest Business Plan Competition

read more